| Indicatie: | DLBCL (NOS), High-grade B-cell lymphoma (MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (DHL/THL) and FL3B, T-cell/histocyte rich B-cell lymphoma, Primary mediastinal B-cell lymphoma, transformed lymphoma (transformed follicular) and R/R after at least 2 lines of systemic therapy.
Age >17 jr |
| Studie: | HOVON161 |
| A phase II non-inferiority study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/refractory Non-Hodgkin Lymphoma |
| Open in: | LUMC |
| Contact: | J.S.P.Vermaat@lumc.nl |
| Status: | OPEN |
|
| Indicatie: | Autoimmune Hemolytic Anemia |
| Studie: | MOM-M281-006 Energy |
| Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study with a Long-term Open-label Extension” |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | rrDLBCL |
| Studie: | LOTIS-5 ADCT402-311 |
| A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5).
|
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | Relapsed or Refractory MM |
| Studie: | Excaliber (CC-220-MM-002) |
| A Ph III, Randomized, Multicnenter, Ope-Label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberdD) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) IN Subjects with Relapsed or REfractroy MM (RRMM) |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | Relapsed or Refractory HL
Leeftijd: ≥ 18 jr |
| Studie: | HOVON 164 Tigerr |
| Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation in Patients in Metabolic Complete Response (TIGERR-HL) |
| Open in: | HAGA |
| Contact: | researchhematologie@hagaziekenhuis.nl |
| Status: | OPEN |
|
| Indicatie: | DLBCL
leeftijd 18-80 jr |
| Studie: | M20-621 |
| A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in
Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell
Lymphoma (DLBCL) (EPCORE DLBCL-2) |
| Open in: | HMC
LUMC |
| Contact: | l.te.boome@haaglandenmc.nl; j.s.p.vermaat@lumc.nl |
| Status: | OPEN |
|
| Indicatie: | Classic FL (prev. Gr 1-3a) stage II, III, IV, R/R
Leeftijd ≥ 18 jaar |
| Studie: | M20-638 |
| A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1) |
| Open in: | LUMC |
| Contact: | J.S.P.Vermaat@lumc.nl |
| Status: | OPEN |
|
| Indicatie: | *DLBCL, NOS
*High-grade BCL + MYC and BCL-2 and/or BCL-6 translocations
*FL grade 3B
Leeftijd ≥ 18 jaar |
| Studie: | M22-132 |
| Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in
Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma |
| Open in: | LUMC |
| Contact: | J.S.P.Vermaat@lumc.nl |
| Status: | OPEN |
|
| Indicatie: | R/R B-cell non-Hodgkin lymphoma (DLBCL, FL, MZL, MCL); leeftijd ≥18 jaar |
| Studie: | CP0201-NHL Atalanta-1 |
| A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma |
| Open in: | LUMC |
| Contact: | J.S.P.Vermaat@lumc.nl |
| Status: | OPEN |
|
| Indicatie: | R-R DLBCL, non-eligible for high-dose chemotherapy (HDC) and ASCT |
| Studie: | DALY |
| A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation |
| Open in: | LUMC |
| Contact: | A.Sijs-Szabo@lumc.nl |
| Status: | OPEN |
|
